CO6710910A2 - Nuevas formas cristalinas y sales de inhibidores de ccr3, para el tratamiento de enfermedades inflamatorias infecciosas e inmunoreguladoras - Google Patents
Nuevas formas cristalinas y sales de inhibidores de ccr3, para el tratamiento de enfermedades inflamatorias infecciosas e inmunoreguladorasInfo
- Publication number
- CO6710910A2 CO6710910A2 CO13090552A CO13090552A CO6710910A2 CO 6710910 A2 CO6710910 A2 CO 6710910A2 CO 13090552 A CO13090552 A CO 13090552A CO 13090552 A CO13090552 A CO 13090552A CO 6710910 A2 CO6710910 A2 CO 6710910A2
- Authority
- CO
- Colombia
- Prior art keywords
- infectious
- salts
- treatment
- immunoregulatory
- inflammatory diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a co-cristales y sales de fórmula (I),Así como a composiciones farmacéuticas que los contienen y a métodos de uso de los mismos como inhibidores de CCR3 útiles en el tratamiento y/o prevención de enfermedades relacionadas con el receptor CCR3, trastornos y enfermedades inflamatorias, infecciosas e inmunorreguladoras, incluyendo asma y enfermedades alérgicas, enfermedad pulmonar obstructiva crónica, infección por microbios patógenos (incluyendo virus), patologías autoinmunes tales como la artritis reumatoide y aterosclerosis, así como degeneración macular asociada a la edad (AMI)), retinopatía diabética y edema macular diahético.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10186901 | 2010-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6710910A2 true CO6710910A2 (es) | 2013-07-15 |
Family
ID=44741339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13090552A CO6710910A2 (es) | 2010-10-07 | 2013-04-08 | Nuevas formas cristalinas y sales de inhibidores de ccr3, para el tratamiento de enfermedades inflamatorias infecciosas e inmunoreguladoras |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US8742115B2 (es) |
| EP (1) | EP2625174B1 (es) |
| JP (1) | JP5794713B2 (es) |
| KR (3) | KR102163874B1 (es) |
| CN (1) | CN103140486B (es) |
| AP (1) | AP3268A (es) |
| AR (1) | AR083353A1 (es) |
| AU (1) | AU2011311530B2 (es) |
| BR (2) | BR112013008211B1 (es) |
| CA (1) | CA2807255C (es) |
| CL (1) | CL2013000488A1 (es) |
| CO (1) | CO6710910A2 (es) |
| CY (1) | CY1116168T1 (es) |
| DK (1) | DK2625174T3 (es) |
| EA (1) | EA029097B1 (es) |
| EC (1) | ECSP13012600A (es) |
| ES (1) | ES2535264T3 (es) |
| GE (1) | GEP20166488B (es) |
| HR (1) | HRP20150419T1 (es) |
| HU (1) | HUE024540T2 (es) |
| IL (1) | IL224269A (es) |
| MA (1) | MA34545B1 (es) |
| ME (1) | ME02040B (es) |
| MX (1) | MX2013003785A (es) |
| MY (1) | MY167898A (es) |
| NZ (1) | NZ605827A (es) |
| PE (1) | PE20140188A1 (es) |
| PH (1) | PH12013500644A1 (es) |
| PL (1) | PL2625174T3 (es) |
| PT (1) | PT2625174E (es) |
| RS (1) | RS53858B1 (es) |
| SG (1) | SG188949A1 (es) |
| SI (1) | SI2625174T1 (es) |
| TW (1) | TWI546294B (es) |
| UA (1) | UA109290C2 (es) |
| UY (1) | UY33655A (es) |
| WO (1) | WO2012045803A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US8680280B2 (en) * | 2012-04-02 | 2014-03-25 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of CRR inhibitors |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| US20200054622A1 (en) * | 2017-04-05 | 2020-02-20 | Alkahest, Inc. | Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors |
| BR112019020798A2 (pt) * | 2017-04-05 | 2020-04-28 | Alkahest Inc | métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3 |
| EP4245295A3 (en) | 2017-04-05 | 2023-11-01 | Alkahest, Inc. | Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors |
| KR20200067859A (ko) * | 2017-10-13 | 2020-06-12 | 알카헤스트 인코포레이티드 | Ccr3-억제제를 사용한 소양증, 건조증, 및 관련 질환을 치료하기 위한 방법 및 조성물 |
| MX2020011114A (es) | 2018-05-15 | 2021-01-29 | Alkahest Inc | Tratamiento de enfermedades asociadas con el envejecimiento con moduladores de la leucotrieno a4 hidrolasa. |
| EA202190463A1 (ru) * | 2018-09-26 | 2021-06-29 | Алкахест, Инк. | Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов |
| CA3180401A1 (en) * | 2020-06-11 | 2021-12-16 | Bartosz SIKORSKI | Methods of improving retina-associated disease outcome using ccr3-inhibitors |
| CA3221177A1 (en) | 2021-11-01 | 2023-05-04 | Meghan Kerrisk Campbell | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7907121L (sv) | 1979-08-27 | 1981-02-28 | Astra Laekemedel Ab | Ftalimidinderivat |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| EP1047675A1 (en) | 1998-01-21 | 2000-11-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| US6140349A (en) | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| WO1999038514A1 (en) | 1998-02-02 | 1999-08-05 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| MXPA04005155A (es) * | 2001-11-29 | 2004-08-11 | Schering Corp | Preparacion de sales farmaceuticas de 4((z) -(4-bromofenil) (etoxiimino)]-1`-((2, 4-dimetil-1 -oxido-3 -piridinil) carbonil]-4` -metil-1, 4`-bipiperidina como antagonistas del receptor ccr5 para el tratamiento de sida y de infecciones de vih relacion |
| EP1596869B1 (en) | 2003-01-21 | 2014-06-04 | New Form Pharmaceuticals Inc. | Novel cocrystallization |
| CA2543419A1 (en) | 2003-10-24 | 2005-05-06 | Leyi Gong | Ccr3 receptor antagonists |
| ES2324224T3 (es) | 2004-02-05 | 2009-08-03 | Schering Corporation | Derivados de piperidina que se pueden utilizar como antagonistas ccr3. |
| JP5017103B2 (ja) * | 2004-06-17 | 2012-09-05 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 薬剤共結晶組成物および関連した使用方法 |
| JP2006137718A (ja) | 2004-11-12 | 2006-06-01 | Astellas Pharma Inc | インドール若しくはインダゾール誘導体 |
| WO2006083390A2 (en) | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxin-3 in eosinophilic esophagitis |
| DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
| JP3701964B1 (ja) * | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
| JP2009533416A (ja) * | 2006-04-12 | 2009-09-17 | ファイザー・リミテッド | ケモカインｃｃｒ５受容体の調節剤としてのピロリジン誘導体 |
| MX2008013468A (es) | 2006-04-20 | 2008-10-30 | Hoffmann La Roche | Nuevos derivados de diazepano. |
| GB0701992D0 (en) | 2007-02-02 | 2007-03-14 | 7Tm Pharma As | Grehlin Receptor Modulators |
| US8008092B2 (en) | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
| TW201000446A (en) | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US8680280B2 (en) | 2012-04-02 | 2014-03-25 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of CRR inhibitors |
| US20130261153A1 (en) | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
-
2011
- 2011-06-10 UA UAA201305572A patent/UA109290C2/ru unknown
- 2011-10-06 CA CA2807255A patent/CA2807255C/en active Active
- 2011-10-06 ME MEP-2015-17A patent/ME02040B/me unknown
- 2011-10-06 PH PH1/2013/500644A patent/PH12013500644A1/en unknown
- 2011-10-06 JP JP2013532190A patent/JP5794713B2/ja active Active
- 2011-10-06 EP EP11764572.1A patent/EP2625174B1/en active Active
- 2011-10-06 TW TW100136338A patent/TWI546294B/zh active
- 2011-10-06 AU AU2011311530A patent/AU2011311530B2/en active Active
- 2011-10-06 KR KR1020177037823A patent/KR102163874B1/ko active Active
- 2011-10-06 SI SI201130394T patent/SI2625174T1/sl unknown
- 2011-10-06 PE PE2013000781A patent/PE20140188A1/es not_active Application Discontinuation
- 2011-10-06 AR ARP110103717A patent/AR083353A1/es unknown
- 2011-10-06 SG SG2013013305A patent/SG188949A1/en unknown
- 2011-10-06 HU HUE11764572A patent/HUE024540T2/hu unknown
- 2011-10-06 US US13/267,417 patent/US8742115B2/en active Active
- 2011-10-06 ES ES11764572.1T patent/ES2535264T3/es active Active
- 2011-10-06 WO PCT/EP2011/067437 patent/WO2012045803A1/en active Application Filing
- 2011-10-06 MX MX2013003785A patent/MX2013003785A/es active IP Right Grant
- 2011-10-06 KR KR1020197025850A patent/KR102239690B1/ko active Active
- 2011-10-06 BR BR112013008211-9A patent/BR112013008211B1/pt active IP Right Grant
- 2011-10-06 DK DK11764572.1T patent/DK2625174T3/da active
- 2011-10-06 MA MA35770A patent/MA34545B1/fr unknown
- 2011-10-06 BR BR122021010665-7A patent/BR122021010665B1/pt active IP Right Grant
- 2011-10-06 AP AP2013006679A patent/AP3268A/xx active
- 2011-10-06 NZ NZ605827A patent/NZ605827A/en unknown
- 2011-10-06 EA EA201300436A patent/EA029097B1/ru unknown
- 2011-10-06 PL PL11764572T patent/PL2625174T3/pl unknown
- 2011-10-06 PT PT11764572T patent/PT2625174E/pt unknown
- 2011-10-06 RS RS20150131A patent/RS53858B1/en unknown
- 2011-10-06 UY UY0001033655A patent/UY33655A/es unknown
- 2011-10-06 GE GEAP201113082A patent/GEP20166488B/en unknown
- 2011-10-06 KR KR1020137008683A patent/KR101844215B1/ko active Active
- 2011-10-06 CN CN201180047995.1A patent/CN103140486B/zh active Active
- 2011-10-06 MY MYPI2013000801A patent/MY167898A/en unknown
-
2013
- 2013-01-17 IL IL224269A patent/IL224269A/en unknown
- 2013-02-19 CL CL2013000488A patent/CL2013000488A1/es unknown
- 2013-04-08 CO CO13090552A patent/CO6710910A2/es unknown
- 2013-05-03 EC ECSP13012600 patent/ECSP13012600A/es unknown
-
2014
- 2014-01-22 US US14/160,646 patent/US20140135307A1/en not_active Abandoned
- 2014-12-17 US US14/572,889 patent/US9233950B2/en active Active
-
2015
- 2015-04-07 CY CY20151100331T patent/CY1116168T1/el unknown
- 2015-04-15 HR HRP20150419TT patent/HRP20150419T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6710910A2 (es) | Nuevas formas cristalinas y sales de inhibidores de ccr3, para el tratamiento de enfermedades inflamatorias infecciosas e inmunoreguladoras | |
| CY1120805T1 (el) | Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης | |
| BR112013023517A2 (pt) | "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica" | |
| ECSP13013040A (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
| DOP2018000020A (es) | Tricíclicos sustituidos y método para usarlos | |
| DOP2015000118A (es) | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina | |
| CO7131357A2 (es) | Compuestos de n-ariltriazol como antagonistas de lpar | |
| CO7131358A2 (es) | Compuestos de n-alquiltriazol como antagonistas de lpar | |
| ECSP13012770A (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina | |
| CR20140305A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de transtornos inflamatorios | |
| CL2011002197A1 (es) | Compuestos derivados de piperidinas sustituidas; composición farmacéutica que los comprende; y su uso como inhibidores de los receptores ccr3 para la prevención y/o el tratamiento de enfermedades tales como asma, alergias, epoc, artritis reumatoide y aterosclerosis. | |
| CR20140554A (es) | Compuestos de acido dimetil-benzoico | |
| MX2014003169A (es) | Ligandos del receptor ep1. | |
| CR20140195A (es) | Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas | |
| UY35138A (es) | Derivados de n- (piridin-2-il) pirimidin-4-amina que contienen un grupo sulfoximina | |
| AR087168A1 (es) | Compuesto derivado de pirimidina sulfonamida | |
| BR112013030264A2 (pt) | ácidos acéticos de benzociclohepteno | |
| DOP2014000034A (es) | Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv) | |
| CR20140516A (es) | Compuestos de pirazol sustituidos como antagonistas de lpar | |
| BR112014013958A8 (pt) | ácidos piperidinila naftilacéticos | |
| BR112013029730A2 (pt) | composição farmacêutica de rosuvastatina cálcica | |
| AR078552A1 (es) | Derivados de feniloxadiazol como agentes inhibidores de las pgds | |
| BR112014009760A2 (pt) | análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo | |
| AR080527A1 (es) | Una pirimidina sustituida como un antagonista del receptor de la postaglandina d2 | |
| BR112015007974A2 (pt) | compostos de carbamato fenil substituídos |